NCT05078931 2025-07-30
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Shanghai Chest Hospital
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT05384015 2025-04-10
PEERS
Fundación GECP
Phase 2 Recruiting
NCT04287829 2024-11-05
PEMMELA
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT04951947 2024-09-19
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05258279 2024-08-28
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
Juntendo University
Phase 2 Active not recruiting
NCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown
NCT06028633 2023-09-13
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Peking University First Hospital
Phase 2 Not yet recruiting
NCT04875585 2022-08-24
INNWOP1
Medical University Innsbruck
Phase 2 Recruiting
NCT04989322 2021-12-08
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
The University of Hong Kong
Phase 2 Unknown